Microbiotica : First patient dosed announcements

“Reaching FPD in two of our Phase 1b trials marks major milestones for Microbiotica. The Scius team supported us in raising visibility of these milestones in key trade press, reinforcing the potential of our microbiome-based medicines in immuno-oncology and inflammatory bowel diseases.”

Tim Sharpington

CEO of Microbiotica

Objectives

Announce the first patients dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking a major step in Microbiotica’s progress towards the clinic.
Reinforce Microbiotica’s leadership in microbiome-based live biotherapeutic products (LBPs) and its transition to a clinical-stage company with LBP’s in development for cancer and gastroenteritis.

Strategy

Developed a coordinated media strategy, including engaging press releases, media pitches, and tailored social media content to maximize engagement.
Targeted key trade media and local press, securing embargoed coverage ahead of the announcement
Distributed news via our GDPR compliant media distribution platforms.

Results

Strong media pick-up across biopharma, clinical trial, and investment publications (e.g., BioWorld, Cambridge Independent, Business Weekly, Endpoints, Labiotech) raising awareness of Microbiotica’s clinical progress
Extensive engagement on LinkedIn, with posts from industry leaders, investors, and partner organizations.